IP Library › Granted Patent US 12697312
Granted Patent B2
US 12697312 · App. 18/479,520 · Granted Aug 4, 2026

Methods and devices for treatment of eyelid ptosis

Inventor: Atif B. D. Collins (Fresno, CA)
A61K31/137A61K31/4174A61M25/0023A61M25/0068
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12697312
App. No.
18/479,520
Granted
Aug 4, 2026
Kind
B2
Abstract

Provided herein is a drug eluting device that can be implanted into the Muller's muscle of a subject to elute a sympathetic stimulant such as oxymetazoline, phenylephrine, norepinephrine, adrenaline, or a combination thereof. Also provided herein are methods to use the device and sympathetic stimulant to treat or prevent eyelid ptosis.

Claims (8)

1 . A drug eluting device for treatment of eyelid ptosis, the drug eluting device having an elongate shape and a length between 3 mm and 4 cm, the drug eluting device comprising a biodegradable polymer and a sympathetic stimulant composition comprising between 0.05 to 5.0 weight percentage of oxymetazoline, wherein the drug eluting device is configured to elute at least 0.2 cc of the sympathetic stimulant composition for at least one month, and wherein the drug eluting device is further configured to be injected into a Muller's muscle of a patient using an injection device configured to allow access to an interior portion of an eye region.

2 . The drug eluting device of claim 1 , wherein the biodegradable polymer is selected from the group consisting of PLGA, PEG-PCL, hyaluronic acid, hydroxyapatite, and chitosan.

3 . The drug eluting device of claim 1 , wherein the sympathetic stimulant composition further comprises an ophthalmologically acceptable carrier.

4 . The drug eluting device of claim 1 , wherein the sympathetic stimulant composition further comprises phenylephrine, epinephrine, a parasympathetic blockade agent, or a combination thereof, and wherein the sympathetic stimulant composition is formulated as a pharmaceutical composition comprising an ophthalmologically acceptable carrier.

5 . The drug eluting device of claim 1 , wherein the length of the drug eluting device corresponds with the length of a tarsal plate of a ptotic eye of the patient.

6 . The drug eluting device of claim 1 , wherein the biodegradable polymer comprises PEG-PCL.

7 . The drug eluting device of claim 1 , wherein the biodegradable polymer comprises hyaluronic acid.

8 . The drug eluting device of claim 1 , wherein the biodegradable polymer comprises chitosan.